Oncolytics Biotech announced positive translational data from its study of pelareorep in patients with squamous cell anal cancer (SCAC). The results show that pelareorep, when combined with a checkpoint inhibitor, drives HPV-specific immune responses, and these changes in the tumor microenvironment are associated with tumor shrinkage.
Key Details
- Mechanism & Efficacy: The data, presented at the SITC 2026 Annual Meeting, showed that pelareorep increased HPV-16-specific T cells and tumor-infiltrating lymphocytes (TILs). All four evaluable patients with expanded TIL clones experienced tumor size reductions (two complete and two partial responses).
- Immune Activation: After just one cycle of treatment, immune-activation biomarker levels more than doubled in nearly all evaluable patients (7 of 8).
- Market Opportunity: The company highlighted HPV-associated cancers as a significant business opportunity for pelareorep, with internal estimates suggesting a potential market size of $3 to $5 billion.